中文版
  • Company news


Investee Company:Immune—onc Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors

Oct 14, 2021

Investee Company:Immune—onc Evaluating IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients With Advanced Solid Tumors...

Oceanpine Capital Appoints Wei Zhu as Venture Partner

Sep 14, 2021

Oceanpine Capital today announced that it has appointed Wei Zhu to the position of Venture Partner...

Investee Company: MingMed has completed raising nearly $50 million in Series A+ round

Sep 13, 2021

MingMed Biotechnology, a startup that develops pharmaceutical products, has completed raising nearly $50 million in its Series A+ round...

Investee Company: Chinese semiconductor firm FerroTec raises $511m to expand manufacturing capability

Sep 07, 2021

FerroTec, a maker of semiconductor wafers, has raised 3.3 billion yuan ($511 million) in a Series B round of financing to advance its manufacturing capability, according to a statement...

Investee Company: Caocao Chuxing Receives 3.8 Billion Yuan in Funding, Sets Headquarters in Suzhou

Sep 07, 2021

Caocao Chuxing, the ride-hailing arm of automaker Geely, announced the completion of Round B financing worth 3.8 billion yuan ($589 million) on Monday...

Investee Company: Wuhan AutoChips has completed its angel financing round with RMB100 million raised

Aug 27, 2021

Beijing (Gasgoo)- Wuhan AutoChips, a wholly controlled subsidiary of Hefei AutoChips, has completed its angel financing round with RMB100 million raised and Chinese smart phone maker OPPO...

Oceanpine Capital held talks with National Engineering Laboratory for Electric Vehicles

Aug 24, 2021

​​​​​​​August 23, 2021, Mr. Dave Chenn, CEO of Oceanpine Capital led the company's investment team visited the National Engineering Laboratory for Electric Vehicles...

Investee Company: Immune-Onc Therapeutics Announces FDA Clearance of IND Application to Initiate First-In-Human Trial of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Advanced Solid Tumors

Aug 13, 2021

Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting immunosuppressive myeloid checkpoints, today announced that the U.S. Food and Drug Administration (FDA) has cleared the

Investee Company: YishengBio Announces PIKA recombinant COVID-19 vaccine received Phase I clinical trial IND clearance from New Zealand

Aug 09, 2021

BEIJING, Aug. 9, 2021, Oceanpine Capital investee company—YishengBio Co., Ltd ("YishengBio") today announced that it received IND clearance for PIKA recombinant COVID-19 vaccine (CHO cell...

Investee company: The Signing Ceremony of LionGo New Energy and Liyang City was successfully held in Liyang

Aug 07, 2021

On August 14,the signing ceremony of Oceanpine Capital investee company— LionGo New Energy and Bieqiao Town, Liyang City was successfully held...
页次:3/10 每页10 总数97    First  Previous  Next  End    转到: